Location Lafayette, Colorado, United States Regions Greater Denver Area, Western US Gender Male
LinkedIn View on LinkedIn
Gino DiSciullo is a member of the board at ClinOne. Gino joined CLS in 2006 and has more than 10 years of experience in venture investing, product development, business development and intellectual property management. Gino has operational experience as the CEO of an early stage life sciences company and has a strong background in immunology.
Prior to joining CLS, Gino was the chief executive officer of APT Pharmaceuticals, a CLS portfolio company. As chief executive officer, Gino raised a $9 million Series A financing, brought the company from concept into Phase II clinical trials and brought on board a world class management team to take the company forward. Gino began his biotech career in a start-up environment working for Cytologix (acquired by DAKO), an early stage diagnostic device company in Boston. In 2001, he joined RCT, an intellectual property licensing and technology investment firm, where he was responsible for business and scientific due diligence and project development management of RCT portfolio companies. At RCT, he also served as manager of Alimmune, a joint venture between RCT and Abgenix (now Amgen).
Gino holds a PhD in immunology and an MS in medical science from the Boston University School of Medicine and a BS in biology from Stonehill College.
